AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01651208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed DVD
Description: The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
Study NCT01232140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRP-guided antibiotic treatment
Description: If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
Study NCT01232140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CRP-guided antibiotic treatment
Description: If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
Study NCT03988218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perceptive tests
Description: many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
Study NCT03988218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: perceptive tests
Description: many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
Study NCT01807884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized oral care
Description: An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
Study NCT01807884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine oral care
Description: Oral suction followed by mouth care and tracheal suction without any subglottic suction
Study NCT02987530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Oral use, 50mg/day
Study NCT02987530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir-cobicistat
Description: Oral use, 800-150mg/day
Study NCT02987530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine-Tenofovir
Description: Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
Study NCT02987530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine-Tenofovir
Description: Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
Study NCT02714127 — intervention group
Intervention type: OTHER
Intervention: Cervicovaginal lavage fluid collection
Description: During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
Study NCT03980964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NMES
Description: Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
Study NCT03980964 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active NMES
Description: Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
Study NCT02947815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A
Study NCT02947815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium Botulinum Toxin Type A
Study NCT03832660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
Study NCT03832660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril/Valsartan
Description: Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
Study NCT04157842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hip replacement with subtrochanteral osteotomy
Description: applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
Study NCT04157842 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: total hip replacement with no osteotomy
Description: just total hip replacement
Study NCT03450109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01005
Description: One gluteal IM injection
Study NCT03450109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: One Subcutaneous injection in the abdominal wall
Study NCT02943993 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study NCT03425604 — intervention group
Intervention type: PROCEDURE
Intervention: Intrauterine insemination
Study NCT01005992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional laser treatment
Description: A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
Study NCT01005992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard scar management
Description: The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
Study NCT04550416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProMark Information and Test Results
Description: Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Study NCT03526003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of esophageal pressure
Description: Measurement of esophageal pressure during posture changes and pneumoperotoneum
Study NCT01323257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
Study NCT01323257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet once daily for 7 days (Trt E, F)
Study NCT01323257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 7 days (Trt A, C, D)
Study NCT01323257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 2 x 400 mg tablet once daily for 7 days (Trt E, F)
Study NCT01323257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 50 mg capsule once daily for 7 days (Trt F)
Study NCT01323257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: 500 mg tablets three times a day for 7 days (Trt C)
Study NCT01855542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline
Description: In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study NCT01855542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plasmalyte
Description: In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study NCT00570765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets were administered orally once daily.
Study NCT00570765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
Study NCT01402271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT01402271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT01402271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT01402271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01402271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pazopanib hydrochloride
Study NCT01402271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Study NCT01402271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01402271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02090309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
Study NCT02090309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: IV injection of 5 ml normal saline 0.9% as a single bolus.
Study NCT04451889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniprobe Alveoflex
Description: Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
Study NCT00109967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 Given IV
Study NCT00109967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: 25 mg given IV
Study NCT01343173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib stop
Description: To stop imatinib after inclusion.
Study NCT00886808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 Intravitreal Injection
Description: single dose iCo-007 Intravitreal Injection
Study NCT00105820 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: System level depression care quality improvement
Study NCT01964859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous skin fibroblasts
Study NCT04122807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac catheter ablation
Description: Cryoablation
Study NCT04122807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheter ablation
Description: Cryoablation
Study NCT01225640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg twice daily (BID) for 14 days
Study NCT01225640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 1200 mg once daily (QD) for 14 days
Study NCT01225640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RHZE
Description: Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
Study NCT02742077 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic-assisted peripheral vascular intervention
Description: Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
Study NCT03201198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Life
Description: The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
Study NCT03201198 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Chair exercises
Description: Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
Study NCT04151017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Description: Conjunctival graft fixation with autologous fibrin glue
Study NCT04228055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIPP2
Description: Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
Study NCT00147355 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ondansetron, ibuprofen, paracetamol
Description: ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study NCT00147355 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron, ibuprofen, paracetamol
Description: Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study NCT00147355 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metoclopramide, ibuprofen, paracetamol
Description: metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study NCT00147355 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metoclopramide, codeine phosphate, ibuprofen, paracetamol
Description: metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study NCT02396979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study NCT02396979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Health Recovery Program
Study NCT04103671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prompt panretinal photocoagulation
Description: Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
Study NCT04103671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25G Pars-plana vitrectomy
Description: Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
Study NCT02709616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized cellular vaccine
Description: Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
Study NCT04232592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inject a solution of stem cell preparation
Description: The control group was injected with a solution of stem cell preparation
Study NCT04232592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inject stem cells
Description: Three dose groups were designed: low dose group, medium dose group and high dose group.
Study NCT01921140 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablets
Description: Olaparib dosing (2X 150mg tablets) following allocated meal
Study NCT01921140 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling
Description: Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
Study NCT01921140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Fasted
Description: 2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
Study NCT01921140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary High Fat
Description: 2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
Study NCT04151017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Graft fixation using 10.0 mononylon
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400/Placebo (3mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400/Placebo (10mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400/Placebo (30mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study NCT00865449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: 25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)
Description: 3/1 (6/2 if DLT);